These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12204499)

  • 1. Effect of long-term therapy with ramipril in high-risk women.
    Lonn E; Roccaforte R; Yi Q; Dagenais G; Sleight P; Bosch J; Suhan P; Micks M; Probstfield J; Bernstein V; Yusuf S;
    J Am Coll Cardiol; 2002 Aug; 40(4):693-702. PubMed ID: 12204499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
    ; Yusuf S; Sleight P; Pogue J; Bosch J; Davies R; Dagenais G
    N Engl J Med; 2000 Jan; 342(3):145-53. PubMed ID: 10639539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
    Teo KK; Mitchell LB; Pogue J; Bosch J; Dagenais G; Yusuf S;
    Circulation; 2004 Sep; 110(11):1413-7. PubMed ID: 15353497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    Yusuf S
    Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.
    Gianni M; Bosch J; Pogue J; Probstfield J; Dagenais G; Yusuf S; Lonn E
    Eur Heart J; 2007 Jun; 28(11):1382-8. PubMed ID: 17395677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramipril: a review of its use in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Drugs; 2002; 62(9):1381-405. PubMed ID: 12076194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on ramipril in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.
    Sumner G; Salehian O; Yi Q; Healey J; Mathew J; Al-Merri K; Al-Nemer K; Mann JF; Dagenais G; Lonn E;
    J Cardiovasc Electrophysiol; 2009 Jul; 20(7):781-7. PubMed ID: 19298567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial.
    Lonn E; Shaikholeslami R; Yi Q; Bosch J; Sullivan B; Tanser P; Magi A; Yusuf S
    J Am Coll Cardiol; 2004 Jun; 43(12):2200-6. PubMed ID: 15193680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.
    Bosch J; Lonn E; Pogue J; Arnold JM; Dagenais GR; Yusuf S;
    Circulation; 2005 Aug; 112(9):1339-46. PubMed ID: 16129815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
    Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.
    Arnold JM; Yusuf S; Young J; Mathew J; Johnstone D; Avezum A; Lonn E; Pogue J; Bosch J;
    Circulation; 2003 Mar; 107(9):1284-90. PubMed ID: 12628949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
    Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
    Gerstein HC
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
    Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II and trials of cardiovascular outcomes.
    Sleight P
    Am J Cardiol; 2002 Jan; 89(2A):11A-16A; discussion 16A-17A. PubMed ID: 11835905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
    Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
    Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).
    Kjøller-Hansen L; Steffensen R; Grande P
    J Am Coll Cardiol; 2000 Mar; 35(4):881-8. PubMed ID: 10732883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.